Discover
INO
Inovio Pharmaceuticals, Inc.
1.19
1 x 1.00
1 x 1.35
bid
ask
+
0.09
8.18%
1 @ 04:00 PM
1.20 +0.01 (0.74%)
| Ytd | -31.61% | |
| 1y | -41.67% |
1.11
day range
1.19
1.03
52 week range
2.98
| Open | 1.12 | Prev Close | 1.10 | Low | 1.11 | High | 1.19 | Mkt Cap | 97.91M |
| Vol | 3.19M | Avg Vol | 2.89M | EPS | -1.58 | P/E | N/A | Forward P/E | -0.48 |
| Beta | 0.83 | Short Ratio | 11.22 | Inst. Own | 33.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 1.19 | 200-d Avg | 1.72 | 1yr Est | 10.67 |
| Income Statement | |||
| Operating Expenses | 21.95M | ||
| Research and Development Expense | 14.07M | ||
| Selling, General and Administrative Expense | 7.88M | ||
| Operating Income | -21.95M | ||
| Net Income | -19.68M | ||
| Net Income Common Stock | -19.68M | ||
| Net Income Common Stock (USD) | -19.68M | ||
| Consolidated Income | -19.68M | ||
| Earnings per Basic Share | -0.28 | ||
| Earnings per Basic Share (USD) | -0.28 | ||
| Earnings per Diluted Share | -0.28 | ||
| Earning Before Interest & Taxes (EBIT) | -19.68M | ||
| Earning Before Interest & Taxes (USD) | -19.68M | ||
| Weighted Average Shares | 69.10M | ||
| Weighted Average Shares Diluted | 69.10M | ||
| Balance Sheet | |||
| Cash and Equivalents | 26.27M | ||
| Cash and Equivalents (USD) | 26.27M | ||
| Investments | 11.41M | ||
| Investments Current | 11.41M | ||
| Current Assets | 39.44M | ||
| Property, Plant & Equipment Net | 8.33M | ||
| Total Assets | 49.78M | ||
| Debt Current | 2.91M | ||
| Total Debt | 8.70M | ||
| Current Liabilities | 37.92M | ||
| Debt Non-Current | 5.79M | ||
| Total Liabilities | 43.71M | ||
| Accumulated Retained Earnings (Deficit) | -1.83B | ||
| Accumulated Other Comprehensive Income | -636.09K | ||
| Shareholders Equity | 6.07M | ||
| Shareholders Equity (USD) | 6.07M | ||
| Assets Non-Current | 10.34M | ||
| Total Debt (USD) | 8.70M | ||
| Liabilities Non-Current | 5.79M | ||
| Trade and Non-Trade Payables | 9.27M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 745.46K | ||
| Net Cash Flow from Financing | 953.79K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -18.00M | ||
| Issuance (Purchase) of Equity Shares | 1.08M | ||
| Net Cash Flow from Investing | 2.64M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 2.64M | ||
| Net Cash Flow from Operations | -21.59M | ||
| Share Based Compensation | 698.74K | ||